Novartis AG may have just won eight more years of market exclusivity for its oral multiple sclerosis drug Gilenya (fingolimod), but the victory also was important for Celgene Corp., which will seek approval for its competing S1P receptor modulator ozanimod next year.
The US Patent and Trademark Office (USPO) Patent Trial and Appeal Board (PTAB) in an inter partes review (IPR) upheld a Gilenya patent related to dosing regimens that expires in 2027
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?